Printer Friendly

FOUNTAIN PHARMACEUTICALS RECEIVES U.S. PATENT

 FOUNTAIN PHARMACEUTICALS RECEIVES U.S. PATENT
 LARGO, Fla., April 22 /PRNewswire/ -- Fountain Pharmaceuticals, Inc.


(NASDAQ: FPHI) announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance with respect to the company's patent application for "A Dressing Material Having Absorbed Thereon a Solvent Dilution Microcarrier Precursor Solution."
 This will be the company's first U.S. patent to incorporate its proprietary SDMC technology. The company's SDMC technology matured to patent status last year in Spain. The company has various other pending worldwide patent applications relating to this technology. Other embodiments of the company's SDMC technologies contained in the allowed patent application will now be prosecuted by the company in separate patent applications which will enjoy the same filing date as the issuing patent.
 Dr. Michael Fountain, chairman of the board and chief executive officer of Fountain Pharmaceuticals, expressed pleasure at the Notice of Allowance of the company's patent, stating, "The allowance of this patent further secures the company in its proprietary technology and differentiates same from other microencapsulation methodologies."
 Fountain Pharmaceuticals, Inc. is a development-stage company that specializes in the application of encapsulated drug delivery systems for the purpose of improving drug compound delivery and enhancing effectiveness of existing products. Fountain also develops proprietary products with applications in the human health care and consumer goods industries.
 /delval/
 -0- 4/22/92
 /CONTACT: Dr. Michael Fountain of Fountain Pharmaceuticals, 813-392-5300/
 (FPHI) CO: Fountain Pharmaceuticals, Inc. ST: Florida IN: MTC SU:


JS-LJ -- PH016 -- 1164 04/22/92 10:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1992
Words:252
Previous Article:MEDAR REPORTS RECORD THREE-MONTH EARNINGS
Next Article:BANCO SANTANDER FIRST QUARTER NET INCOME INCREASES 19.35 PERCENT; OPERATING PROFIT UP 32.46 PERCENT; DIVIDEND INCREASES 11.6 PERCENT


Related Articles
BARCOLENE/PENN CHAMP AND FOUNTAIN PHARMACEUTICALS TEAM UP FOR EXCITING NEW SUNTAN PROGRAM
FOUNTAIN PHARMACEUTICALS SIGNS OPTION AGREEMENT
FOUNTAIN PHARMACEUTICALS ANNOUNCES INTENDED REGISTRATION OF ADDITIONAL SHARES
FOUNTAIN PHARMACEUTICALS, INC. ANNOUNCES REGISTRATION OF RESTRICTED SECURITIES
FOUNTAIN PHARMACEUTICALS ENTERS LICENSING AGREEMENT WITH SPIRIG A.G.
FOUNTAIN PHARMACEUTICALS ANNOUNCES UNITED STATES PATENT FOR CORE LYPHAZOME TECHNOLOGY
FOUNTAIN PHARMACEUTICALS ANNOUNCES EXTENSION OF NASDAQ LISTING
Fountain Pharmaceuticals, Inc. Announces 'Letter of Intent'
Fountain Pharmaceuticals, Inc. Announces The Sale Of $2.5 Million Of Convertible Preferred Stock And Changes In Board Membership
Fountain Pharmaceuticals, Inc. and Dermik Announce Intentions on Future Collaboration.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters